Traders sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading hours on Tuesday. $111.29 million flowed into the stock on the tick-up and $285.49 million flowed out of the stock on the tick-down, for a money net flow of $174.20 million out of the stock. Of all equities tracked, Johnson & Johnson had the 3rd highest net out-flow for the day. Johnson & Johnson traded up $0.41 for the day and closed at $138.34
JNJ has been the subject of several research analyst reports. Cowen and Company reiterated an “outperform” rating and issued a $155.00 price objective (up previously from $147.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. UBS AG reiterated a “buy” rating and issued a $148.00 price objective on shares of Johnson & Johnson in a research report on Thursday, August 31st. Jefferies Group LLC lifted their price objective on Johnson & Johnson from $157.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, October 16th. Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Finally, Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company an “outperform” rating in a research report on Thursday, October 19th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $143.70.
The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. The firm has a market capitalization of $371,650.00, a P/E ratio of 19.33, a P/E/G ratio of 2.80 and a beta of 0.82.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. During the same period in the previous year, the firm earned $1.68 earnings per share. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. equities research analysts predict that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.43%. Johnson & Johnson’s dividend payout ratio is presently 58.33%.
A number of hedge funds have recently bought and sold shares of JNJ. State Street Corp lifted its holdings in Johnson & Johnson by 4.3% during the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after acquiring an additional 6,656,371 shares in the last quarter. BlackRock Inc. lifted its holdings in Johnson & Johnson by 2.6% during the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after acquiring an additional 4,332,612 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Johnson & Johnson by 717.9% during the second quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after acquiring an additional 3,289,763 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Johnson & Johnson by 1.5% during the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after acquiring an additional 3,023,110 shares in the last quarter. Finally, Parametric Portfolio Associates LLC lifted its holdings in Johnson & Johnson by 47.9% during the second quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock worth $1,054,433,000 after acquiring an additional 2,581,562 shares in the last quarter. Hedge funds and other institutional investors own 65.61% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.truebluetribune.com/2017/11/21/investors-sell-johnson-johnson-jnj-on-strength-jnj.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.